Business Trip

In this week’s episode, we chat with Matt Zorn, an attorney at Yetter Coleman with expertise in DEA law, especially regarding psychedelics. Matt is currently challenging the DEA’s decision to schedule 5 new tryptamines, he recently argued Kathryn Tucker’s psilocybin “Right To Try” case against the DEA, and previously co-led Sue Sisley’s DEA case related to cannabis scheduling. Matt also writes the drug policy newsletter On Drugs.Credits: Created by Greg Kubin and Matias SerebrinskyHost: Matias Serebrinsky & Greg KubinProduced by Jonathan A. Davis & Zack FrankFind us at businesstrip.fmFollow us on Instagram and Twitter!Theme music by Dorian LoveAdditional Music: Distant Daze by Zack Frank

In this week’s special episode, Matias chats with Dr. Rachel Yehuda and Zach Haigney at Soho House in New York City. The episode was recorded in front of a live audience. Dr. Yehuda has spent the last 30 years doing research on PTSD and trauma and is leading the MDMA-assisted therapy research at the US Veterans Affairs Medical Center.  She is the Director at the Mental Health Patient Care Center at the James J. Peters VA Medical Center, Director of the Center for Psychedelic Psychotherapy and Trauma Research at Mount Sinai Hospital, as well as Professor of Psychiatry and Neuroscience at the Icahn School of Medicine at Mount Sinai Hospital. Zach Haigney writes the Trip Report by Beckley Waves, a newsletter about the science, policy, and business of psychedelics.Credits: Created by Greg Kubin and Matias SerebrinskyHost: Matias Serebrinsky & Greg KubinProduced by Jonathan A. Davis & Zack FrankFind us at businesstrip.fmFollow us on Instagram and Twitter!Theme music by Dorian LoveAdditional Music: Distant Daze by Zack Frank

In Episode 18, we chat with Jonathan Sabbagh and Myriam Barthes, the co-founders of Journey Clinical, a platform that enables licensed therapists to offer ketamine-assisted psychotherapy (KAP). Journey Clinical provides licensed therapists with an on-demand KAP-trained medical team, customized treatments for each client, and a portal to connect with other therapists and educational resources.In this episode, we discuss:The journey from idea to 100+ therapist membersHow ketamine-assisted therapy works and the Journey Clinical's vision for the futureBalancing growth with protecting the relationship between patient and therapistCredits: Created by Greg Kubin and Matias SerebrinskyHost: Matias Serebrinsky & Greg KubinProduced by Jonathan A. Davis & Zack FrankFind us at businesstrip.fmFollow us on Instagram and Twitter!Theme music by Dorian LoveAdditional Music: Distant Daze by Zack Frank

In today’s episode, we chat with Lucia Huang, the CEO and co-founder of Osmind, an electronic health record software system for treatment resistant mental health practices that is already in over 300 clinics. In this episode, we discuss:How Osmind makes data-driven decisions Osmind’s quick growth in only 2 yearsWhat it will take for insurance to cover ketamine therapy, as well as other psychedelic therapiesCreated by Greg Kubin and Matias SerebrinskyHost: Matias Serebrinsky & Greg KubinProduced by Jonathan A. Davis & Zack FrankMarketing by DaisyMae VanValkenburghFind us at businesstrip.fmFollow us on Instagram and Twitter!Theme music by Dorian LoveAdditional Music: Distant Daze by Zack Frank

In today’s episode, we chat with Tim Schlidt, a partner at Palo Santo. Palo Santo is a fund investing in psychedelic therapeutics. Palo Santo’s portfolio includes companies like Eleusis, Tactogen, and Journey Clinical.In this episode, we discuss:Tim’s background in healthcare financeInvesting in classic psychedelic compounds vs. 2nd generation compoundsHallmarks of a good first meeting with a prospective investmentCreated by Greg Kubin and Matias SerebrinskyHost: Matias Serebrinsky & Greg KubinProduced by Jonathan A. Davis & Zack FrankMarketing by DaisyMae VanValkenburghFind us at businesstrip.fmFollow us on Instagram and Twitter!Theme music by Dorian LoveAdditional Music: Distant Daze by Zack Frank

Today’s episode features Dillan Dinardo and Tom Ray, the co-founders of Mindstate Design Labs. Mindstate has a unique framework to design psychedelic compounds using what they call the “primer probe method.” This method involves combining a known psychedelic with a non-psychedelic compound. Mindstate just raised an $11.5M seed round.In this episode, we discuss:Tom and Dillan’s experience in YCombinator and raising an $11.5M seed roundTom’s friendship with the late psychedelic chemist Alexander ShulginMindstate’s lead programsThe role of mystical states in the healing processCreated by Greg Kubin and Matias SerebrinskyHost: Matias Serebrinsky & Greg KubinProduced by Jonathan A. Davis & Zack FrankMarketing by DaisyMae VanValkenburghFind us at businesstrip.fmFollow us on Instagram and Twitter!Theme music by Dorian Love

Today’s episode features Amy Emerson, the CEO of MAPS Public Benefit Corporation (PBC), which is a fully owned subsidiary of MAPS, and its purpose is to commercialize MDMA-assisted therapy. We discuss the MAPS PBC and it’s business model for MDMA-assisted therapy.In this episode, we discuss:MAPS’ protocol and strategy behind FDA clinical trial for PTSDAmy’s views on the state of the industry, patents, and how to prioritize accessibilityThe unique business model between MAPS and MAPS PBCPsychedelics for kidsCreated by Greg Kubin and Matias SerebrinskyHost: Greg Kubin and Matias SerebrinskyProduced by Jonathan A. Davis & Zack FrankMarketing by DaisyMae VanValkenburghFind us at businesstrip.fmFollow us on Instagram and Twitter!Theme music by Dorian LoveAdditional music: Focus Does the Girl by Muted Circus

In today’s episode, we discuss what it’s like being a psychologist who owns a psychedelic clinic. Genesee Herzberg is the co-founder of Sage Integrative Health, an integrative clinic in Berkeley, CA that offers ketamine-assisted therapy (KAP), psychotherapy, somatic therapy, and acupuncture. Genesee discusses her holistic approach to healing, and shares her experience bootstrapping her clinic and setting up a non-profit to make KAP more affordable.In this episode, we discuss:Ketamine-assisted psychotherapy and the difference between high and low dose ketamine treatmentsWhat it takes to get a for-profit clinic off the ground while running a non-profit organizationSage Institute’s mission to make ketamine-assisted psychotherapy affordable for everyoneGenesee’s long term goals for the future of psychedelic medicineCreated by Greg Kubin and Matias SerebrinskyHost: Matias Serebrinsky & Greg KubinProduced by Jonathan A. Davis & Zack FrankMarketing by DaisyMae VanValkenburghRead the transcript here.Find us at businesstrip.fmFollow us on Instagram and Twitter!Theme music by Dorian LoveAdditional music: Flocean by Zack Frank

In today’s episode, we explore the therapeutic application of DMT across a range of diseases and conditions including Alzheimer’s, stroke, and organ transplants. While much of the attention in psychedelic medicine has been on their ability to address neuropsychiatric indications, research suggests that psychedelics like DMT have a far wider therapeutic potential. The episode features three biotech companies developing DMT therapies:  Algernon, Psilera, and Pharmadrug.In this episode, we discuss:DMT therapies for organ transplants, stroke patients and substance abuse disordersResearch supporting NN-DMT’s antioxidative and anti-inflammatory effects and the receptors it targetsBeing a private company vs. public company in psychedelicsNN-DMT5-MeO-DMTBioavailabilityDMT transdermal patchSigma-1DonepezilDr. Rick StrassmanAngiogenesisOrphan Drug DesignationCreated by Greg Kubin and Matias SerebrinskyHost: Matias SerebrinskyProduced by Jonathan A. Davis & Zack FrankMarketing by DaisyMae VanValkenburghRead the transcript here.Find us at businesstrip.fmFollow us on Instagram and Twitter!Theme music by Dorian LoveAdditional music: Copley Beat by Blue Dot Sessions, Simplify by Little Glass Men, Pedalrider by Blue Dot Sessions, Running Waters by Jason Shaw, and Neon Drip by Blue Dot Sessions

Episode 10 features Lars Wilde, co-founder and Chief Business Officer of Compass Pathways, a mental health company with an initial focus on psilocybin therapy for Treatment-Resistant Depression.In this episode, we discuss:Lars’ experience overcoming Treatment-Resistant Depression with psilocybinThe nuances of clinical trials and psilocybin dosing protocolsCompass Pathways’ Intellectual Property strategyWhat additional indications and therapies Compass Pathways is interested inLinks to topics discussed in this episode:Compass Pathways, Lars WildeCOMP360SSRI, SNRIChristian Angermayer, Robin Carhart-Harris, Michael PollanVivaneoQuercis PharmaTRD (Therapy-Resistant Depression)Compass Phase 2B TrialJazz PharmaceuticalsCompass Pathways 2 US patentsOregon Psilocybin Therapy Measure 109Read the transcript here.Watch episode 10 on YouTube.Created by Greg Kubin and Matias SerebrinskyHosts: Matias Serebrinsky and Greg KubinProduced by Jonathan A. Davis & Zack FrankMarketing by DaisyMae VanValkenburghFind us at businesstrip.fmFollow us on Instagram and Twitter!Theme music by Dorian LoveAdditional music: River Meditation by Jason Shaw and Thea by Muted Circus